PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Cialis users sue Lilly .pdf


Original filename: Cialis users sue Lilly.pdf
Author: Kathryn Taylor

This PDF 1.5 document has been generated by Acrobat PDFMaker 11 for Word / Adobe PDF Library 11.0, and has been sent on pdf-archive.com on 09/08/2016 at 18:32, from IP address 50.79.x.x. The current document download page has been viewed 177 times.
File size: 35 KB (1 page).
Privacy: public file




Download original PDF file









Document preview


Cialis users sue Lilly, claiming drug has ties to
skin cancer
August 5, 2016
John Russell
KEYWORDS ELI LILLY AND CO. / LEGAL ISSUES / LAWSUITS / HEALTH CARE BUSINESSES / HEALTH
CARE & LIFE SCIENCES / HEALTH CARE & INSURANCE / LAW

Seven men who took Cialis pills to treat erectile dysfunction sued Indianapolis drugmaker Eli Lilly and Co.
this week, claiming they later suffered from skin cancer that was related to the medicine.
The plaintiffs, from Ohio, Illinois, Texas and other states, filed separate but similar complaints Tuesday in
U.S. District Court in Indianapolis, saying that Lilly knew or should have known the drug’s mechanism of
action presented “significant risk of exacerbating melanoma.”
The suits cite studies in several medical journals that the plaintiffs claim link Cialis’ mechanism of action
to melanoma. The mechanism, which inhibits an enzyme associated with flow of blood in the penis, is
known as a PDE5 inhibitor.
One of the studies, published in the medical journal Cell Reports, determined PDE5 inhibitors lead to
increased tumor growth, although that study did not specifically study the effects of Cialis, the suit said.
Another study, published in the Journal of the American Medical Association Internal Medicine, reported
that users of a PDE5 inhibitor called sildenafil citrate, used in Pfizer’s erectile drug Viagra, exhibited an 84
percent increase in risk of developing or encouraging invasive melanoma.
The law firm that filed the suits, Cory Watson of Birmingham, Alabama, said it has filed more than 100
suits against Pfizer and more than 20 suits against Lilly in recent months.
“The pharmaceutical industry has known for a very long time that inhibition of PDE5 has been associated
with an increased risk of melanoma,” said Kristian Rasmussen, a lawyer at the Alabama firm, which
specializes in representing injury victims. “That information has slowly come to light over the last few
years in the public domain.”
Lilly responded that it has reviewed the studies and has found no evidence that Cialis, also known as
tadalafil, causes melanoma.
“We’ve reviewed data from multiple sources pertaining to melanoma skin cancer and tadalafil, and have
concluded that based on the available data, a causal association has not been established,” Lilly
spokesman Scott MacGregor wrote in an email. “Lilly and regulatory agencies continue to monitor this
question.”
The plaintiffs, who took Cialis for periods ranging from one year to nine years, said they were treated for
various skin cancers on fingers, chest, back and head.
The plaintiffs are alleging negligence, fraudulent misrepresentation, defective design and failure to
properly test the drug and warn patients. They are seeking unspecified damages.
Cialis rang up sales of $2.3 billion last year.


Document preview Cialis users sue Lilly.pdf - page 1/1

Related documents


PDF Document cialis users sue lilly
PDF Document drugmaker pfizer decides not to break up business ibj
PDF Document tadalafil bulk supplier cas 171596 29 5 dosage side effect
PDF Document lilly shares rise after alimta cancer drug patent
PDF Document lilly buying developer of pain
PDF Document bjc201526a


Related keywords